Erratum to: Immunochemotherapy plus lenalidomide for high-risk mantle cell lymphoma with measurable residual disease evaluation

Haematologica. 2024 Aug 1;109(8):2749-2752. doi: 10.3324/haematol.2024.285845.

Authors

Zachary D Epstein-Peterson¹, Esther Drill², Umut Aypar³, Connie Lee Batlevi¹, Philip Caron¹, Ahmet Dogan³, Pamela Drullinsky¹, John Gerecitano¹, Paul A Hamlin¹, Caleb Ho³, Allison Jacob⁴, Ashlee Joseph¹, Leana Laraque¹, Matthew J Matasar¹, Alison J Moskowitz¹, Craig H Moskowitz¹, Chelsea Mullins⁴, Colette Owens¹, Gilles Salles¹, Heiko Schöder⁵, David J Straus¹, Anas Younes¹, Andrew D Zelenetz¹, Anita Kumar⁶

Affiliations

¹ Lymphoma Service, Division of Hematologic Malignancies, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY.
² Department of Biostatistics and Epidemiology, Memorial Sloan Kettering Cancer Center, New York, NY.
³ Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY.
⁴ Adaptive Biotechnologies, Seattle, WA.
⁵ Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
⁶ Lymphoma Service, Division of Hematologic Malignancies, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY. kumara@mskcc.org.

No abstract available

Publication types

Letter
Published Erratum

MeSH terms

Antineoplastic Combined Chemotherapy Protocols* / therapeutic use
Humans
Immunotherapy / methods
Lenalidomide* / administration & dosage
Lenalidomide* / therapeutic use
Lymphoma, Mantle-Cell* / drug therapy
Lymphoma, Mantle-Cell* / pathology
Lymphoma, Mantle-Cell* / therapy
Neoplasm, Residual* / diagnosis
Thalidomide / administration & dosage
Thalidomide / analogs & derivatives
Thalidomide / therapeutic use

Substances

Lenalidomide
Thalidomide